Regencell Bioscience Holdings (Regencell Bioscience Holdings) Debt-to-Equity

: 0.04 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

Regencell Bioscience Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.44 Mil. Regencell Bioscience Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.03 Mil. Regencell Bioscience Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $12.03 Mil. Regencell Bioscience Holdings's debt to equity for the quarter that ended in Jun. 2023 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Regencell Bioscience Holdings's Debt-to-Equity or its related term are showing as below:

RGC' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.16 Med: -0.92 Max: 0.05
Current: 0.04

During the past 5 years, the highest Debt-to-Equity Ratio of Regencell Bioscience Holdings was 0.05. The lowest was -1.16. And the median was -0.92.

RGC's Debt-to-Equity is ranked better than
84.68% of 855 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs RGC: 0.04

Regencell Bioscience Holdings Debt-to-Equity Historical Data

The historical data trend for Regencell Bioscience Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

-1.13

-1.16

-0.92

0.05

0.04

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity					-0.92	-	0.05	-	0.04

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Debt-to-Equity falls into.

Regencell Bioscience Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Regencell Bioscience Holdings's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.438	+	0.025)	/	12.03
	=	0.04

Regencell Bioscience Holdings's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.438	+	0.025)	/	12.03
	=	0.04

Regencell Bioscience Holdings (NAS:RGC) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Regencell Bioscience Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.